Releases · ARTEBONE®

Stock exchange and press releases of BBS will be published on these pages. Releases are published in Finnish and in English.

Contact information for the media: info@bbs-artebone.fi from which you can also request additional media material.

Company releases

30.12.2022
BBS-Bioactive Bone Substitutes Plc - Insider information: BBS updates estimate of the CE marking approval schedule of ARTEBONE® Paste

14.12.2022
BBS-Bioactive Bone Substitutes Plc: Financial calendar and Annual General Meeting in 2023

09.12.2022
BBS-Bioactive Bone Substitutes: 69% of the warrants 1-2022 (WA1) used for the subscription of shares, company raises EUR 213 000 in gross proceeds

18.11.2022
BBS-Bioactive Bone Substitutes Oyj: The subscription period for the first warrant series starts on 21 November 2022 – the subscription price is EUR 0.92 per share

18.11.2022
BBS-Bioactive Bone Substitutes – Inside information: The first audit completed by the Notified Body, CE marking process may continue as planned

04.11.2022
BBS-Bioactive Bone Substitutes announces plans to withdraw its dual listing on Nasdaq First North Growth Market Sweden

04.11.2022
BBS-Bioactive Bone Substitutes has resolved on a share issue without consideration to the company itself

07.10.2022
Jari Kortesluoma appointed as CFO and member of the management team of BBS-Bioactive Bone Substitutes Plc

31.08.2022
BBS-Bioactive Bone Substitutes Plc: Managers’ Transactions – Pekka Jalovaara

31.08.2022
BBS-Bioactive Bone Substitutes Plc: Managers’ Transactions – Ahti Paananen

31.08.2022
BBS-Bioactive Bone Substitutes Plc: Change in BBS-Bioactive Bonesubstitutes Plc’s management

25.08.2022
BBS-Bioactive Bone Substitutes Plc: Managers’ Transactions – Oili Halonen

25.08.2022
BBS-Bioactive Bone Substitutes Plc: Managers’ Transactions – Pekka Jalovaara

25.08.2022
BBS-Bioactive Bone Substitutes Plc: Managers’ Transactions – Jarmo Halonen

25.08.2022
BBS-Bioactive Bone Substitutes Plc: Half-Year Financial Report, 1 January – 30 June 2022 (unaudited)

08.08.2022
Changes in the BBS-Bioactive Bone Substitutes Plc’s Management Team

28.06.2022
BBS-Bioactive Bone Substitutes Plc: Trading on BBS’s warrants begins on First North Growth Market Finland

08.06.2022
BBS-Bioactive Bone Substitutes Plc’s rights issue raised gross proceeds of EUR 3.5 million

06.05.2022
BBS-Bioactive Bone Substitutes Plc: BBS arranges a rights issue of approximately maximum 4.5 MEUR with additional warrants

29.04.2022
BBS-Bioactive Bone Substitutes Plc: Decisions of the Annual General Meeting 2022

17.03.2022
BBS-Bioactive Bone Substitutes Plc: Decisions of the Extraordinary General Meeting 2022

09.03.2022
BBS Bioactive Bone Substitutes Plc has filed the CE-marking application of Artebone® bone void filler to the authorities

24.02.2022
Invitation to the Extraordinary General Meeting of Bbs-Bioactive Bone Substitutes Plc

24.02.2022
BBS-Bioactive Bone Substitutes Plc: Financial Statements Review 1.1.-31.12.2021 (unaudited)

23.02.2022
Drawdown of an advance pursuant to financing arrangement between BBS-Bioactive Bone Substitutes Plc and RiverFort to strengthen the working capital position

11.01.2022
BBS-Bioactive Bone Substitutes Plc: US Patent for the Manufacture of ARTEBONE® product

10.12.2021
BBS-Bioactive Bone Substitutes Plc: Financial calendar and Annual General Meeting in 2022

19.11.2021
BBS-Bioactive Bone Substitutes Plc: Conversion of convertible notes pursuant to financing arrangement between BBS-Bioactive Bone Substitutes Plc ja Riverfort Global Opportunities PCC Ltd

17.11.2021
BBS-Bioactive Bone Substitutes Plc: Claims of the patent application for the manufacturing of the ARTEBONE® product have been approved in the USA

30.09.2021
BBS-Bioactive Bone Substitutes Plc has agreed on a capital facility to strengthen the company's working capital – further enables the CE marking application

07.09.2021
BBS-Bioactive Bone Substitutes Plc: Animal test results completed contributing on their part to submitting the CE marking application

25.08.2021
BBS-Bioactive Bone Substitutes Plc: CORRECTION: Half-Year Report January 1st –June 30th 2021 (Unaudited)

25.08.2021
BBS-Bioactive Bone Substitutes Plc: Half-Year Report January 1st –June 30th 2021 (Unaudited)

29.04.2021
BBS-Bioactive Bone Substitutes Plc - CORRECTION: Decisions of the Annual General Meeting 2021

28.04.2021
BBS-Bioactive Bone Substitutes Plc: Decisions of the Annual General Meeting 2021

26.04.2021
BBS-Bioactive Bone Substitutes Plc: Submission of CE marking application for ARTEBONE® products moves to August

08.04.2021
BBS-Bioactive Bone Substitutes Plc: CORRECTION TO THE INVITATION TO THE ANNUAL GENERAL MEETING

07.04.2021
BBS-Bioactive Bone Substitutes Plc: INVITATION TO THE BBS-BIOACTIVE BONE SUBSTITUTES PLC’S ANNUAL GENERAL MEETING (AGM)

31.03.2021
BBS-Bioactive Bone Substitutes Plc: ANNUAL REPORT 2020 has been published

24.02.2021
BBS-Bioactive Bone Substitutes Plc: Financial Statements Review 1.1.-31.12.2020 (unaudited)

01.02.2021
BBS-Bioactive Bone Substitutes Plc: CFO will change on 1 February, 2021

11.01.2021
BBS-Bioactive Bone Substitutes Plc: New Schedule Estimate for the CE Marking of Company’s ARTEBONE® Product

23.12.2020
BBS-Bioactive Bone Substitutes Plc: Correction to the release of BBS-Bioactive Bone Substitutes Plc published on 21.12.2020 at 16:30 CET

21.12.2020
BBS-Bioactive Bone Substitutes Plc: BBS-Bioactive Bone Substitutes' financial calendar and Annual General Meeting in 2021

08.12.2020
BBS-Bioactive Bone Substitutes Plc: The information published in the Company Announcement by BBS-Bioactive Bone Substitutes Plc. on 9 November 2020 at 8:45 has proved to be incorrect

09.11.2020
BBS-Bioactive Bone Substitutes Plc: The whole patent regarding the product ARTEBONE® has been accepted in the USA

07.08.2020
BBS-Bioactive Bone Substitutes Plc: The CE marking application of the Company’s ARTEBONEⓇ Paste product is in progress

26.06.2020
BBS-Bioactive Bone Substitutes Plc: Directed share issue to shareholder

25.06.2020
BBS-Bioactive Bone Substitutes Plc: Managers' Transactions

24.06.2020
BBS-Bioactive Bone Substitutes Plc: Final results of the successful rights issue - oversubscribed by 49 percent

12.06.2020
BBS-Bioactive Bone Substitutes Plc: Today is the last day of trading in subscription rights

29.05.2020
BBS-Bioactive Bone Substitutes Plc: The Prospectus of Rights Issue has been published on the Company’s website today

26.05.2020
BBS-Bioactive Bone Substitutes Plc: BBS-Bioactive Bone Substitutes Plc postpones the Annual General Meeting to a later date

26.05.2020
BBS-Bioactive Bone Substitutes Plc: The Board of Directors of BBS-Bioactive Bone Substitutes Plc. decided on a subscription rights issue and publishes the prospectus and issue terms

20.05.2020
BBS-Bioactive Bone Substitutes Plc: BBS-Bioactive Bone Substitutes Plc. plans to arrange a rights issue of approximately 5.5 MEUR

09.04.2020
BBS-Bioactive Bone Substitutes Plc: Financial Statements for 2019 have been published

07.04.2020
BBS-Bioactive Bone Substitutes Plc: The patent regarding the product ARTEBONE® has been granted in the USA

07.04.2020
BBS-Bioactive Bone Substitutes Plc: BBS-Bioactive Bone Substitutes Plc postpones the Annual General Meeting to a later date

27.03.2020
BBS-Bioactive Bone Substitutes Plc: BBS-Bioactive Bone Substitutes Plc has received a working capital loan to secure its financing

20.03.2020
BBS-Bioactive Bone Substitutes Plc: Financial Statements Review 1.1.-31.12.2019 (unaudited)

19.02.2020
BBS-Bioactive Bone Substitutes Plc: We are pleased to announce that the clinical result of ARTEBONE® is positive yielding an outcome similar to patient’s own bone graft

22.10.2019
BBS-Bioactive Bone Substitutes Plc: The patent application regarding a bone protein preparation has been accepted in Canada

14.10.2019
BBS-Bioactive Bone Substitutes Plc: A new CEO has been selected for BBS

22.03.2019
Correction to Financial Statement Bulletin of BBS-Bioactive Bone Substitutes Plc, published 22th March 2019 at 9:00 CET

22.03.2019
Financial Statement Bulletin

15.03.2019
BBS-Bioactive Bone Substitutes Plc: Correction to the invitation to annual general meeting of BBS-Bioactive Bone Substitutes Plc published on 15.03.2019 at 12:00 CET

15.03.2019
Bbs-Bioactive Bone Substitutes Plc: INVITATION TO ANNUAL GENERAL MEETING

30.08.2018
BBS-Bioactive Bone Substitutes Plc: BBS-Bioactive Bone Substitutes Plc (BBS) Interim Report 1.1.-30.6.2018 (unaudited)

21.06.2018
BBS-Bioactive Bone Substitutes Plc: BBS's ARTEBONE® -product as an example in the Manual of classification of medical devices

27.04.2018
BBS-Bioactive Bone Substitutes Plc: The special condition fulfilled, over 2 million euros of loans is written off

29.03.2018
BBS-Bioactive Bone Substitutes Plc: Decisions of the Annual General Meeting

08.03.2018
BBS-Bioactive Bone Substitutes Plc: INVITATION TO ANNUAL GENERAL MEETING

Press releases and Investor News

22.12.2022
BBS's Management Meets with Minister of Economic Affairs and MP

28.11.2022
Reminder: The subscription period for the first warrant series of BBS ends on 2 December, trading of warrants ends on 30 November

08.11.2022
Update on BBS-Bioactive Bone Solutions’ CE marking process

18.05.2022
BBS-Bioactive Bone Substitutes Plc: US authorities publish a supplementary patent application filed by the company

13.05.2019
BBS strengthens the Board of Directors with acclaimed biomaterials expert Dr. Ilkka Kangasniemi

Older releases can be found from our news archive.